Holen Sie sich die Stockscreener-App
133.35
0.49%
0.60
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo.co
Neurocrine Bio. stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Canada
What analysts say about Neurocrine Biosciences Inc. stockFree Investment Community - jammulinksnews.com
What drives Neurocrine Biosciences Inc. stock priceAccelerated investment success - Autocar Professional
Neurocrine Biosciences Inc. Stock Analysis and ForecastBreakthrough profits - Autocar Professional
Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN
Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative
Truist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Truist Financial - MarketBeat
Is Neurocrine Biosciences Inc. a good long term investmentExplosive capital gains - Autocar Professional
Daily Turnover | The turnover of Neurocrine Biosciences on 7/18 was $100.31 Million, Ranking 820 - AInvest
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - simplywall.st
Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment - TipRanks
Lobbying Update: $80,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Nasdaq
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.
Neurocrine reports positive results from Crenessity trial - MSN
Neurocrine Biosciences shares rise 2.09% after-hours after presenting new analysis on CAH treatment. - AInvest
Neurocrine shares new one-year data from trial of Crenessity for CAH - Yahoo Finance
Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients - Stock Titan
Neurocrine shares registry data showing CAH treatment challenges - StreetInsider
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 - PR Newswire
New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter
Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating - MarketScreener
What makes Neurocrine Biosciences Inc. stock price move sharplyMassive Upside Selection - beatles.ru
NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients - Nasdaq
Endometriosis Market to Reach New Heights in Growth by 2034, - openPR.com
Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 - 富途牛牛
Neurocrine presents one-year data showing weight improvements with CRENESSITY - StreetInsider
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting - Eastern Progress
Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference - StreetInsider
Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025 - Nasdaq
Neurocrine Biosciences: CRENESSITY's Breakthrough in CAH Positions NBIX for Sustained Growth - AInvest
Neurocrine reports positive results from Crenessity trial (NBIX) - Seeking Alpha
Neurocrine reports positive one-year data for CAH treatment By Investing.com - Investing.com India
Neurocrine presents one-year data from study of Crenessity - TipRanks
CRENESSITY's Groundbreaking CAH Data Positions Neurocrine Biosciences for Dominance in a High-Impact Market - AInvest
Neurocrine reports positive one-year data for CAH treatment - Investing.com
New Clinical Data: CRENESSITY Achieves Breakthrough 30% Steroid Reduction in Adult CAH Treatment - Stock Titan
Neurocrine Biosciences (NASDAQ:NBIX) Given New $174.00 Price Target at UBS Group - MarketBeat
Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock - Investing.com Australia
Neurocrine Biosciences: Insider Selling StormShould Investors Be Alarmed? - AInvest
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):